R. Katherine Alpaugh

6.0k total citations · 1 hit paper
112 papers, 4.5k citations indexed

About

R. Katherine Alpaugh is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, R. Katherine Alpaugh has authored 112 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 39 papers in Molecular Biology and 29 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in R. Katherine Alpaugh's work include Cancer Cells and Metastasis (24 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Cancer Genomics and Diagnostics (22 papers). R. Katherine Alpaugh is often cited by papers focused on Cancer Cells and Metastasis (24 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Cancer Genomics and Diagnostics (22 papers). R. Katherine Alpaugh collaborates with scholars based in United States, Japan and Sweden. R. Katherine Alpaugh's co-authors include Louis M. Weiner, André Rogatko, James D. Marks, L M Weiner, Massimo Cristofanilli, Jonathan D. Cheng, Gregory P. Adams, Adrian M. McCall, Eva Horak and Robert Schier and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

R. Katherine Alpaugh

110 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

2001 507 citations Gregory P. Adams, R. Katherine Alpaugh et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Katherine Alpaugh United States	37	2.6k	1.7k	1.1k	996	859	112	4.5k
Andrea T. Hooper United States	32	2.6k 1.0×	2.8k 1.7×	1.0k 0.9×	475 0.5×	1.2k 1.4×	56	5.8k
Margareta M. Mueller Germany	31	1.7k 0.7×	1.8k 1.1×	972 0.8×	517 0.5×	1.0k 1.2×	48	4.6k
Stefania Bellone United States	41	2.4k 0.9×	1.8k 1.1×	1.4k 1.2×	609 0.6×	761 0.9×	155	5.4k
Serenella M. Pupa Italy	35	2.3k 0.9×	2.3k 1.4×	1.5k 1.3×	1.4k 1.4×	833 1.0×	94	4.8k
Olivier Gires Germany	42	3.4k 1.3×	2.8k 1.7×	1.3k 1.2×	462 0.5×	1.3k 1.5×	109	6.2k
Alexander Berndt Germany	35	1.3k 0.5×	1.7k 1.0×	722 0.6×	736 0.7×	656 0.8×	137	4.1k
Jay S. Desgrosellier United States	19	1.6k 0.6×	2.7k 1.6×	759 0.7×	415 0.4×	770 0.9×	30	4.9k
Thomas E. Darga United States	25	3.1k 1.2×	1.6k 1.0×	2.5k 2.2×	491 0.5×	746 0.9×	34	5.4k
Claire Vanpouille‐Box United States	30	3.2k 1.2×	1.3k 0.8×	2.7k 2.3×	697 0.7×	667 0.8×	68	5.4k
André Pèlegrin France	38	1.5k 0.6×	1.6k 1.0×	606 0.5×	1.9k 1.9×	397 0.5×	148	4.4k

Countries citing papers authored by R. Katherine Alpaugh

Since Specialization

Citations

This map shows the geographic impact of R. Katherine Alpaugh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Katherine Alpaugh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Katherine Alpaugh more than expected).

Fields of papers citing papers by R. Katherine Alpaugh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Katherine Alpaugh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Katherine Alpaugh. The network helps show where R. Katherine Alpaugh may publish in the future.

Co-authorship network of co-authors of R. Katherine Alpaugh

This figure shows the co-authorship network connecting the top 25 collaborators of R. Katherine Alpaugh. A scholar is included among the top collaborators of R. Katherine Alpaugh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Katherine Alpaugh. R. Katherine Alpaugh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhatia, Aarti, Ranee Mehra, Jessica R. Bauman, et al.. (2025). Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head & Neck. 47(9). 2373–2382. 2 indexed citations

Fernandez, Sandra V., Shilpa Rao, Fathima Sheriff, et al.. (2023). Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing. International Journal of Molecular Sciences. 24(21). 15779–15779. 2 indexed citations

Macfarlane, Alexander W., R. Katherine Alpaugh, Essel Dulaimi, et al.. (2021). Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunology Immunotherapy. 70(7). 1893–1906. 8 indexed citations

Slifker, Michael, Jianming Pei, Jacqueline Talarchek, et al.. (2020). Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer. International Journal of Molecular Sciences. 21(4). 1290–1290. 12 indexed citations

Franco‐Barraza, Janusz, Ralph Francescone, Neelima Shah, et al.. (2017). Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence. eLife. 6. 78 indexed citations

Adams, Daniel L., Diane K. Adams, R. Katherine Alpaugh, et al.. (2016). Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiology Biomarkers & Prevention. 25(7). 1037–1042. 63 indexed citations

Haas, Naomi B., Ian Quirt, Sébastien J. Hotte, et al.. (2014). Phase II trial of vorinostat in advanced melanoma. Investigational New Drugs. 32(3). 526–534. 47 indexed citations

Tu, Yifan, Dawn L. Hershman, Kapil N. Bhalla, et al.. (2014). A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Research and Treatment. 146(1). 145–152. 51 indexed citations

Ali, Siraj M., R. Katherine Alpaugh, Sean R. Downing, et al.. (2014). Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy. Journal of Clinical Oncology. 32(25). e88–e91. 40 indexed citations

10.

Alpaugh, R. Katherine, et al.. (2008). Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy. The Journal of Immunology. 180(9). 6392–6401. 135 indexed citations

11.

Borghaei, Hossein, R. Katherine Alpaugh, Patricia Bernardo, et al.. (2007). Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. Journal of Immunotherapy. 30(4). 455–467. 20 indexed citations

12.

Tang, Yong, Jianlong Lou, R. Katherine Alpaugh, et al.. (2007). Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen. The Journal of Immunology. 179(5). 2815–2823. 103 indexed citations

13.

Cohen, Steven J., R. Katherine Alpaugh, Steve Gross, et al.. (2006). Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 6(2). 125–132. 157 indexed citations

14.

Tang, Yong, et al.. (2004). Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format. Journal of Biological Chemistry. 279(52). 53907–53914. 95 indexed citations

15.

Cheng, Jonathan D., Roland L. Dunbrack, Matthildi Valianou, et al.. (2002). Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.. PubMed. 62(16). 4767–72. 198 indexed citations

16.

Alpaugh, R. Katherine, C McAleer, Bruce J. Giantonio, et al.. (1998). Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.. PubMed. 4(8). 1903–14. 36 indexed citations

17.

Alpaugh, R. Katherine, Louis M. Weiner, Robert Persson, & Bo Persson. (1998). Overview of clinical trials employing antibody-targeted superantigens. Advanced Drug Delivery Reviews. 31(1-2). 143–152. 8 indexed citations

18.

Weiner, Louis M., et al.. (1995). Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.. PubMed. 55(20). 4586–93. 112 indexed citations

19.

Weiner, Louis M., Joseph I. Clark, David B. Ring, & R. Katherine Alpaugh. (1995). Clinical Development of 2B1, a Bispecific Murine Monoclonal Antibody Targeting c-erbB-2 and FcγRIII. Journal of Hematotherapy. 4(5). 453–456. 48 indexed citations

20.

Weiner, Louis M., et al.. (1993). Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.. The Journal of Immunology. 151(5). 2877–2886. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact